Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials
D. Halpin (Exeter, United Kingdom), C. Vogelmeier (Marburg, Germany), A. Mackay (London, United Kingdom), K. Mezzi (Basel, Switzerland), P. Goyal (Basel, Switzerland), P. Gupta (Hyderabad, India), K. Kostikas (Basel, Switzerland), J. Wedzicha (London, United Kingdom)
Source: International Congress 2018 – COPD management
Session: COPD management
Session type: Thematic Poster
Number: 4394
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Halpin (Exeter, United Kingdom), C. Vogelmeier (Marburg, Germany), A. Mackay (London, United Kingdom), K. Mezzi (Basel, Switzerland), P. Goyal (Basel, Switzerland), P. Gupta (Hyderabad, India), K. Kostikas (Basel, Switzerland), J. Wedzicha (London, United Kingdom). Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials. 4394
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019
Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study Source: Eur Respir J 2016; 48: 1030-1039 Year: 2016
INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD Source: Eur Respir J 2014; 44: 1548-1556 Year: 2014
COPD patients continuing salmeterol or switched to tiotropium: a retrospective analysis of clinical trial data Source: Eur Respir J 2007; 30: Suppl. 51, 612s Year: 2007
Switch from LABA+ICS to a LABA/LAMA combination in symptomatic women with COPD – an analysis of the observational DACCORD study Source: International Congress 2018 – Pharmacological management of COPD Year: 2018
Effectiveness of combination therapy with tiotropium in COPD. A secondary analysis of the UPLIFT trial Source: Annual Congress 2009 - Functional insights into COPD Year: 2009
Comparison of cardiovascular safety in a pooled analysis of COPD trials comparing tiotropium with salmeterol Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013
Fluticasone/formoterol combined in a single aerosol inhaler vs budesonide/formoterol for the treatment of asthma: A non-inferiority trial Source: Annual Congress 2011 - Asthma: control and treatment Year: 2011
Cost-effectiveness of formoterol turbuhaler versus salbutamol as reliever therapy in asthma: results from the RELIEF worldwide randomised effectiveness study Source: Eur Respir J 2002; 20: Suppl. 38, 43s Year: 2002
Efficacy and safety of QVA149 compared with salmeterol/fluticasone combination (SFC) in Chinese patients with moderate-to-severe COPD: A subgroup analysis from the LANTERN study Source: International Congress 2015 – Safety of and interactions between current treatments for asthma and COPD Year: 2015
Indacaterol/glycopyrronium vs tiotropium or glycopyrronium in treatment naive COPD patients: a pooled analysis Source: International Congress 2018 – COPD management Year: 2018
Pooled analysis of the efficacy and safety from two non-interventional studies of fluticasone propionate/formoterol pMDI Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Cost-effectiveness of tiotropium versus salmeterol: A trial-based analysis followed by a model-based extrapolation Source: Annual Congress 2011 - Understanding the burden of chronic respiratory diseases: what decision makers need to know Year: 2011
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo Source: Eur Respir J 2006; 28: Suppl. 50, 764s Year: 2006
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
Effect of triple therapy with extra-fine BDP/FF/GB pMDI vs non-triple maintenance therapies on severe COPD exacerbations. A pooled analysis of the TRILOGY, TRINITY and TRIBUTE studies. Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020
Twice-daily aclidinium bromide in COPD patients: A pooled analysis of lung function in the ACCORD-COPD I and ATTAIN trials Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial Source: ERJ Open Res, 7 (3) 00255-2021; 10.1183/23120541.00255-2021 Year: 2021